Johnson & Johnson (NYSE:JNJ) Shares Acquired by 1900 Wealth Management LLC

Posted by Defense World Staff on May 4th, 2023

1900 Wealth Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 9,033 shares of the company’s stock after buying an additional 218 shares during the period. 1900 Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,596,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co boosted its holdings in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after buying an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P boosted its stake in Johnson & Johnson by 88.9% during the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after purchasing an additional 82,429 shares during the period. AMI Investment Management Inc. boosted its stake in Johnson & Johnson by 8.8% during the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after purchasing an additional 1,475 shares during the period. Equitable Holdings Inc. boosted its stake in Johnson & Johnson by 4.9% during the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after purchasing an additional 2,119 shares during the period. Finally, USS Investment Management Ltd boosted its stake in Johnson & Johnson by 2.4% during the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after purchasing an additional 20,528 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 1st. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Guggenheim assumed coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price target on the stock. Finally, Atlantic Securities dropped their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Stock Down 1.3 %

Shares of NYSE:JNJ opened at $162.87 on Thursday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99. The company has a market cap of $424.16 billion, a PE ratio of 34.07, a price-to-earnings-growth ratio of 2.78 and a beta of 0.53. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $183.35. The firm has a 50 day simple moving average of $158.10 and a 200 day simple moving average of $167.02.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.67 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.92%. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio is 94.56%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.20% of the stock is owned by insiders.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.